Graft Versus Host Disease (GvHD): Forecast in Asia-Pacific Markets to 2028

1.1 List of Tables
1.2 List of Figures

2.1 Steady Growth Expected in the GvHD Marketplace from 2018-2028
2.2 Unmet Needs Remain Largely Unattained in GvHD Management
2.3 Opportunity Remains for GvHD Prophylaxis Candidates
2.4 Jakavi Approval for Both Acute and Chronic GvHD Will Drive Sales
2.5 What Do Physicians Think?

3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification and Prognosis
4.2.1 aGvHD
4.2.2 cGvHD

6.1 Overview
6.2 Diagnosis
6.3 Treatment

7.1 Overview
7.2 Lack of Efficacious Treatment
7.3 Lack of Treatment Options for Steroid-Refractory GvHD
7.4 Identification of Patients with High- or Low-Risk Severe Disease
7.5 Lack of Standardized Protocols for Prophylaxis Regimens and Off-Label Treatments

8.1 Overview
8.1.1 Targeting Niche Subgroups within GvHD
8.1.2 Adopting Treatments from Hematologic Indications
8.1.3 Development of Kinase Inhibitors
8.2 Clinical Trials Design
8.2.1 Current Clinical Trial Design
8.2.2 Lack of Consensus on Clinical Trial Endpoints in Current Trial Designs
8.2.3 Patient Exclusion Issues in Current Clinical Trial Designs
8.2.4 Limitations and Future Outlook

9.1 Overview
9.2 Innovative Pipeline Approaches

10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 Australia
10.4.2 India
10.4.3 China
10.4.4 South Korea
10.4.5 Japan

Table 1: GvHD: Key Metrics in the 5GM
Table 2: Grading System of Organ Involvement in aGvHD
Table 3: Global Severity of Chronic GvHD
Table 4: Risk Factors for GvHD
Table 5: Innovative Approaches for GvHD, 2019
Table 6: Clinical Benchmark of Key Pipeline Drugs - GvHD Treatment
Table 7: Clinical Benchmark of Key Pipeline Drugs - GvHD Prophylaxis
Table 8: Commercial Benchmark of Key Pipeline Drugs - GvHD Treatment
Table 9: Commercial Benchmark of Key Pipeline Drugs - GvHD Prophylaxis
Table 10: Key Events Impacting Sales for GvHD, 2018-2028
Table 11: GvHD Market - Global Drivers and Barriers, 5GM, 2018-2028
Table 12: Key Historical and Projected Approval/Launch Dates for GvHD
Table 13: Key Projected Patent Expiry Dates for GvHD
Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global (5GM) Sales Forecast for GvHD, by Country, 2018 and 2028
Figure 2: Competitive Assessment of the Pipeline GvHD Treatments Benchmarked Against the SOC, Corticosteroids
Figure 3: Pathology of Acute GvHD
Figure 4: 5GM, Diagnosed Incidence of aGvHD per 100 First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018
Figure 5: 5GM, Diagnosed Incidence of cGvHD per 100 First Allogeneic HSCT Cases, All Ages, Both Sexes, 2018
Figure 6: Case Flow Map of aGvHD and cGvHD
Figure 7: Sources Used for First Allogeneic HSCT
Figure 8: Sources Used for aGvHD and cGvHD in First Allogeneic HSCT
Figure 9: Sources Used for aGvHD Grades
Figure 10: Sources Used for cGvHD Severity
Figure 11: Sources Used for 100-Day Mortality of aGvHD and One-Year Mortality of cGvHD
Figure 12: Sources Used for Three-Year Diagnosed Prevalent Cases of aGvHD and cGvHD
Figure 13: 5GM, Diagnosed Incident Cases of First Allogeneic HSCT Cases, Both Sexes, All Ages, 2018
Figure 14: 5GM, Diagnosed Incident Cases of aGvHD in First Allogeneic HSCT Cases, Both Sexes, All Ages, 2018
Figure 15: 5GM, Diagnosed Incident Cases of cGvHD in First Allogeneic HSCT Cases, Both Sexes, All Ages, 2018
Figure 16: 5GM, Age-Specific Diagnosed Incident Cases of aGvHD and cGvHD in First Allogeneic HSCT Cases, Both Sexes, 2018
Figure 17: 5GM, Diagnosed Incident Cases of aGvHD by Grade, Both Sexes, All Ages, 2018
Figure 18: 5GM, Diagnosed Incident Cases of cGvHD by Severity, Both Sexes, All Ages, 2018
Figure 19: 5GM, 100-Day Mortality in Diagnosed Incident Cases of aGvHD, Both Sexes, All Ages, 2018 and 2028
Figure 20: 5GM, One-Year Mortality in Diagnosed Incident Cases of cGvHD, Both Sexes, All Ages, 2018
Figure 21: 5GM, Three-Year Diagnosed Prevalent Cases of aGvHD, Both Sexes, All Ages, 2018
Figure 22: 5GM, Three-Year Diagnosed Prevalent Cases of cGvHD, Both Sexes, All Ages, 2018
Figure 23: Unmet Needs and Opportunities in GvHD
Figure 24: Overview of the Development Pipeline in GvHD
Figure 25: Key Phase II/III Trials for Pipeline Agents Expected to Be Licensed for GvHD in the 5GM During the Forecast Period
Figure 26: Competitive Assessment of the Marketed and Pipeline Drugs for GvHD Treatment Benchmarked Against the SOC, Corticosteroids
Figure 27: Competitive Assessment of the Marketed and Pipeline Drugs for GvHD Prophylaxis Benchmarked Against the SOC, Methotrexate
Figure 28: 5GM Sales Forecast by Country for GvHD in 2018 and 2028
Figure 29: Global (5GM) Sales Forecast by Class for GvHD in 2018 and 2028
Figure 30: 5GM Sales Forecast by Patient Population for GvHD in 2018 and 2028
Figure 31: Sales Forecast by Class for GvHD in Australia in 2018 and 2028
Figure 32: Sales Forecast by Class for GvHD in India in 2018 and 2028
Figure 33: Sales Forecast by Class for GvHD in China in 2018 and 2028
Figure 34: Sales Forecast by Class for GvHD in South Korea in 2018 and 2028
Figure 35: Sales Forecast by Class for GvHD in Japan in 2018 and 2028